Dini Gianluca, Di Cara Giuseppe, Ferrara Pietro, Striano Pasquale, Verrotti Alberto
Department of Pediatrics, University of Perugia, Perugia, Italy.
Department of Pediatrics, Campus Bio-Medico University, Rome, Italy.
Neuropsychiatr Dis Treat. 2023 Sep 26;19:2013-2025. doi: 10.2147/NDT.S417676. eCollection 2023.
Despite the introduction of new anti-seizure medications in recent years, approximately one-third of the epileptic population continues to experience seizures. Recently, the anti-obesity medication fenfluramine (FFA) has been successfully repurposed, and it has received approval from various regulatory agencies for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. The potential antiseizure effects of FFA were initially observed in patients with photosensitive epilepsy in the 1980s but it was not rigorously explored as a treatment option until 30 years later. This narrative review aims to provide an overview of the historical progression of FFA's use, starting from initial clinical observations to preclinical studies and, ultimately, successful clinical trials in the field of epilepsy.
尽管近年来引入了新的抗癫痫药物，但仍有大约三分之一的癫痫患者继续发作。最近，抗肥胖药物芬氟拉明（FFA）已成功实现用途转换，并已获得多个监管机构的批准，用于治疗与德雷维特综合征和伦诺克斯-加斯托综合征相关的癫痫发作。FFA的潜在抗癫痫作用最初在20世纪80年代的光敏性癫痫患者中被观察到，但直到30年后才作为一种治疗选择进行严格研究。本叙述性综述旨在概述FFA从最初的临床观察到临床前研究，最终到癫痫领域成功临床试验的使用历史进程。
